{
  "docId": "019de071-f579-76ad-bea5-b34da2c83a75",
  "docSlug": "563487226462eb4ab63630eb9b74a5cf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 42,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a dark blue callout box to emphasize the final conclusion/takeaway.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/16",
  "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75",
  "deckJsonHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75.json",
  "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.725
      },
      "kind": "callout",
      "text": "Durvalumab plus GemCis is an effective first-line therapy, and could become a new standard of care, for patients with advanced BTC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d01d9d1-a4dc-4404-a274-dba8e57fb73a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.117,
        "w": 0.92,
        "x": 0.04,
        "y": 0.233
      },
      "kind": "list",
      "text": "TOPAZ-1 is the first global Phase III trial to report positive results testing immunotherapy plus chemotherapy as first-line treatment for advanced BTC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c4a5c43-0ee2-47df-9da0-82639f0948f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.167,
        "w": 0.92,
        "x": 0.04,
        "y": 0.367
      },
      "kind": "list",
      "text": "TOPAZ-1 met its primary endpoint at the prespecified interim analysis: durvalumab plus GemCis demonstrated statistically significant and clinically meaningful prolonged overall survival compared with placebo plus GemCis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f797031-c811-456a-a95e-3f486abb0daa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.117,
        "w": 0.92,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Durvalumab did not add additional toxicity to that observed with GemCis, and no new safety signals were identified from the known safety profiles of each individual treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d743c7e-df4d-47c9-9d99-4d82f8e49abf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.25,
        "x": 0.04,
        "y": 0.975
      },
      "kind": "source-note",
      "text": "BTC, biliary tract cancer; GemCis, gemcitabine and cisplatin.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f52aee49-73fc-4417-9fa0-a4ef9b150ba9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.067,
        "w": 0.23,
        "x": 0.033,
        "y": 0.067
      },
      "kind": "title",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bcd40c1-f613-4607-aaf5-bdca4ec89841",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6ec33630-d3da-4ab3-b91d-14160631cf18",
      "evidence": "The slide presents a clear and concise key takeaway, which is a typical component of the AIDA model, aiming to grab attention, generate interest, create desire, and encourage action.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 9,
      "beatId": "5bf1753c-e4a0-4e18-b568-73af9c0043f2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results for Imfinzi TOPAZ-1 and HIMALAYA, demonstrating their effectiveness",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}